Category Archives: Science: Biology

Cutting edge research is happening on a daily basis in our modern world, Keep up to date with our Press Release services.

Fast, Gentle and Easy Single Cell Isolation, Upcoming Webinar Hosted by Xtalks


There has been an urgent need for fast and easy single cell dispensing technology that is at the same time gentle to the cells and can preserve their viability and integrity.

Single cell sorting and isolation has traditionally been a bottleneck in the workflows for single cell cloning, single cell genomics, rare cell isolation, synthetic biology and other applications. Existing techniques such as fluorescence-activated cell sorting (FACS) often leads to compromised cell viability and poor outgrowth, contamination, clogging, in addition to the operational complexity and high maintenance requirement, while manual limiting dilution is inefficient, unreliable and highly labor-intensive. As such, there has been an urgent need for fast and easy single cell dispensing technology that is at the same time gentle to the cells and can preserve their viability and integrity. There is also a need for quick sorting of tens of thousands of cells for single cell genomics, such as sample prep for 10x Genomics workflow.

In this presentation, the speaker will discuss an innovative technology to address these needs. It combines the benefits of three key technologies: microfluidics, flow cytometry and liquid dispensing. The unique combination of these techniques enables users to accomplish single cell sorting and dispensing in one step, providing fast, easy and gentle sorting and isolation of single cells. This will simplify and empower a number of single cell applications, including cell line development, single cell genomics and proteomics, cell line engineering and CRISPR, monoclonal antibody development, synthetic biology, and rare cell isolation such as circulating tumor cells (CTCs) and circulating fetal cells.

Join John Lee, Applications Scientist, Namocell in a live webinar on Thursday, October 7, 2021 at 1pm EDT to discover how this technology can help optimize a single cell workflow and deliver desired results.

For more information, or to register for this event, visit Fast, Gentle and Easy Single Cell Isolation.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Cayman Offers Multidisciplinary Lipid-Based Drug Delivery Capabilities


This triad partnership provides Cayman clients a one-stop shop for lipid nanoparticle development—from R&D to final formulation.

Cayman Chemical, leader in the synthesis, purification, and characterization of lipids, has partnered with NanoImaging Services and T&T Scientific to provide a multi-pronged platform that synthesizes, characterizes, and formulates lipid-based nanoparticles to help researchers and pharmaceutical companies alike develop vaccines and other novel therapeutics from the preclinical stage on through clinical phases and commercial manufacturing.

The use of lipid-based nanoparticles offers significant advantages in drug delivery, boosting bioavailability, reducing toxicity, and enabling the administration of therapeutics that are prone to instability. Therapeutics that would benefit from nanoparticle delivery systems require custom lipids to create novel formulations to optimize delivery and release of their payload. “Cayman’s team of synthetic organic and medicinal chemists specialize in building high-purity, GMP-quality components (phospholipids, sterols, sphingolipids, PEGylated lipids, glycerolipids, anionic lipids, and cationic lipids) used to assemble a lipid nanoparticle,” said Stephen Barrett, Vice President of Research, Development, and Production at Cayman.

The development of a lipid-based nanoparticle delivery system in part requires morphological characterization such as evaluation of particle size, shape, and surface details. “NanoImaging Services has been providing cryoEM services for the visualization of viral and lipid nanoparticles since 2007 and offers a range of characterization services including qualitative and quantitative analysis to help support drug delivery and vaccine development projects,” said Ben Schenker, Chief Commercial Officer at NanoImaging Services.

Once developed, these lipid nanoparticles must be formulated for eventual clinical use. T&T Scientific offers lipid nanoparticle formulations as well as lipoplex formulation services. “Pairing the custom lipid synthesis capabilities and expertise at Cayman with T&T Scientific’s expertise as a contract development and manufacturing organization, developing and manufacturing vaccines and therapeutics will help enable rapid translation to the clinic with clients’ novel and innovative gene therapies,” said Graham Taylor, President and Chief Technology Officer at T&T Scientific.

“This triad partnership provides Cayman clients a one-stop shop for lipid nanoparticle development—from R&D to final formulation. We have always offered services for custom synthesis of complex lipids, but by now also coordinating lipid nanoparticle formulation and characterization,” said Dr. Michael Pisano, Vice President of Contract Research at Cayman, “we have the expertise to nurture the development of more effective delivery systems for a wide range of gene therapies, enzyme-replacement therapies, vaccines, and other therapeutics to address unmet needs in cancer, infectious diseases, and other illnesses.”

Contact Cayman to inquire about custom synthesis of nanoparticle components or additional characterization and formulation services. You can learn more about the lipid components Cayman stocks in house from our article on Lipid-Based Nano Drug Delivery.

About Cayman Chemical

Cayman Chemical Company helps make research possible by supplying scientists worldwide with biochemical tools used to understand cancer, neurochemistry, oxidative injury, endocrinology, atherosclerosis, and other human health challenges. Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others for use as research reagents and qualified standards. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination. In addition, we offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques. Cayman performs generic drug development and production in both Ann Arbor, Michigan and Neratovice, Czech Republic.

For more information, follow Cayman Chemical on Twitter, Facebook, and LinkedIn.

About NanoImaging Services

NanoImaging Services, Inc. launched in 2007 to provide imaging services to the pharmaceutical, biotechnology and nanotechnology communities. We have since built a client-focused organization with a reputation for expertise, reliability and collaboration. NIS is committed to expanding our service capacity through microscope acquisition, workflow automation, recruitment and training of top talent, and development of new service offerings. Our state-of-the-art facilities include a range of electron microscopes, sample preparation equipment and computational infrastructure to support structural biology, nanoparticle characterization and chemistry workflows. With recent acquisitions, NIS has become the largest and most comprehensive provider of TEM, cryoEM and microED services to the industrial life science market. For more information, visit: http://www.nanoimagingservices.com.

About T&T Scientific

T&T Scientific is home to the world’s most advanced and cutting-edge lipid nanoparticle formulation and manufacturing technologies. We provide pharmaceutical services and technologies for the preparation and manufacturing of novel lipid nanoparticle and liposome based nanomedicines, including vaccines and therapeutics. T&T offers a wide range of GMP and non-GMP contract services including research and formulation development, analytical method and manufacturing process development, and clinical or commercial drug product manufacturing with sterile fill-finish capabilities in a 15,000 sq. ft. state-of-the-art facility. T&T’s mission is to provide a comprehensive range of high-quality products and services, with quick delivery to support customers’ research, development, and manufacturing needs. T&T Scientific supports clients around the globe from their main facility in Knoxville, TN. For more information, visit: https://ttscientific.com/.

Share article on social media or email:



American College of Healthcare Trustees (ACHT) announces plans to organize a Datathon, seeks sponsors, mentors, participants and data sources


The American College of Healthcare Trustees continues to work hard to enable the cross-pollination of ideas from different areas of healthcare. We are excited to spearhead the development of the Datathon to address unmet real world clinical needs that could be solved with data.

The American College of Healthcare Trustees (ACHT), a social enterprise that promotes exceptional and ethical governance, leadership and decision-making in healthcare, announces plans to organize a Datathon. The Dathaton will bring together diverse stakeholders from various fields, including but not limited to healthcare, medicine, technology and data science, in order to solve an important real world clinical problem.

Similar to a Hackathon, during this collaboration data scientists, clinicians, medical students, computer scientists, students, entrepreneurs and others get together to use real world information and applied data science tools and techniques to develop actionable intelligence and potential solutions to important real world problem(s) of today.

The American College of Healthcare Trustees is looking for several Sponsors for the Datathon, who will be instrumental in formulating the specific goals for this effort and/or who can provide access to anonymized data that would be crucial to solving the identified problem(s). There are multiple benefits to the Sponsors, including direct access to a highly motivated and skilled team of interdisciplinary experts, exclusively focused on the real world issue at hand for the duration of the Datathon. Other benefits include positive brand recognition and associated goodwill as well as empowering young people to pursue multidisciplinary work in healthcare by demonstrating the power of a joint effort at the intersection of medicine, technology, data science and business.

In addition to Sponsors, ACHT is seeking a broad range of participants across the disciplines mentioned, as well as seasoned professionals to serve as mentors for the Datathon. The American College of Healthcare Trustees is also interested in hearing from a variety of stakeholders in healthcare about the real world issues they would like to see addressed and/or ideas for dataset(s) to use. Please submit your ideas via this short form.

“The American College of Healthcare Trustees continues to work hard to enable the cross-pollination of ideas from different areas of healthcare,” said David Levien, MD, MBA, FACS, President, CEO and Board Chairman of the American College of Healthcare Trustees. “We are excited to spearhead the development of the Datathon to address unmet clinical needs that could be solved with data.”

For additional details about the Datathon or to discuss potential Sponsorship opportunities please contact David Levien, MD, MBA, FACS (david.levien@facht.org, 844-322-4867, https://calendly.com/dlevien48) or Roxanne Bruce MBA, DrBA (roxanne.bruce@facht.org, 207-521-7001).

About ACHT

The American College of Healthcare Trustees (ACHT) is a national professional association dedicated to promoting high performing, competent, qualified, ethical governance and leadership in healthcare that is person-centered and accountable by providing continuing education, resources, and networking.

Share article on social media or email:

BSCS Science Learning, Kendall Hunt Announce BSCS Biology: Understanding for Life


“The addition of Understanding for Life strengthens our science offerings as well as meets the needs of classrooms nationwide,” said Kendall Hunt K-12 Vice President Charley Cook.

BSCS Science Learning and Kendall Hunt are pleased to announce BSCS Biology: Understanding for Life, the next generation in a line of BSCS Biology programs. This newest offering meets the needs of a changing discipline and is ready for implementation now through a staged release process during the 2021-22 school year.

Understanding for Life advances the mission of BSCS to transform science teaching and learning through research-driven innovation by integrating the three-dimensional disciplinary shifts called for in the latest Next Generation Science Standards (NGSS).

This full-year, high school level biology program presents inquiry-based, research-driven curriculum that has been designed for the (NGSS). Real-world phenomena and challenges motivate learning of scientific concepts and practices, enabling students to build a deep understanding of life science that will serve them for life. Understanding for Life’s labs, activities and assessments build 21st century collaboration skills while allowing teachers to track students’ progress toward science learning outcomes.

BSCS Executive Director Danny Edelson said, “This program is the next step for BSCS and for high school biology teachers across the country. In it, we have combined the rigor and inquiry that teachers expect from BSCS with the three-dimensional pedagogical approach called for by the Next Generation Science Standards.”

“Throughout the years, Kendall Hunt has been proud to work with BSCS to emphasize the development of students’ problem-solving and inquiry skills through programs such as A Human Approach and Science Tracks,” said Kendall Hunt K-12 Vice President Charley Cook. “The addition of Understanding for Life strengthens our science offerings as well as meets the needs of classrooms nationwide.”

About Kendall Hunt:

Kendall Hunt has a 75-year history of providing innovative educational solutions. As the publisher of hands-on science, mathematics and gifted curricula for grades K-12, they also offer the only free, certified Illustrative Mathematics for grades K-12. In conjunction with offering a variety of stand-alone K-12 products, ConstructEd, a division of Kendall Hunt, allows both schools and teachers to create made-to-order, customized textbooks or digital products using existing products or creating their own. For more information, visit https://k12.kendallhunt.com/.

_______________________

About BSCS Science Learning:

BSCS Science Learning is an independent nonprofit organization dedicated to transforming science education through research-driven innovation. An innovator in science education since 1958, BSCS has brought inquiry learning experiences to millions of students and teachers around the world. Today, BSCS conducts research on science education and uses research-driven development processes to create instructional materials, teacher professional learning programs, and leadership development programs that foster improvements in science teaching and learning.

Share article on social media or email:

Utilizing Metallographic Techniques to Investigate Failures


Fatique Striations Failure Analysis

Failure Analysis and Metallography will discuss:- Ductile and brittle fracture surfaces and how to recognize them- Fatigue fracture types- Failure due to corrosion- Failures caused by microstructural changes- Failures due to embrittlement

The 9-11 attack of the World Trade Center buildings 1, 2 and 7, and the 1979 failure of the Three Mile Island Unit 2 nuclear reactor are classic examples of failures that required an analysis on what happened to the materials during very serious failures. Examples will be discussed in this webinar. Registration is available HERE.

Metallographers are brought in to analyze and identify what caused the problems and how they can be dealt with to stop the problem and any potential further damage and also to determine what can be done to prevent future problems.

Buehler is sponsoring a webinar “Metallography and Failure Analysis” on September, 28, 2021, 9:30am CST (China Standard Time). George Vander Voort, exclusive consultant to Buehler, will present this educational webinar. Failure analysis consists of studies to determine why a component failed in service.

With more than 50 years of experience in metallography and failure analysis, George will discuss fundamental principles of performing a failure analysis, as well as utilizing metallographic techniques to investigate failures and determine why they occurred and how they can be prevented.

Practical examples of the use of light optical and electron microscopy will be demonstrated through examples of failed specimens with a variety of case histories and studies, including:

  • Ductile and brittle fracture surfaces and how to recognize them
  • Fatigue fracture types
  • Failure due to corrosion
  • Failures caused by microstructural changes
  • Failures due to embrittlement
  • Highlight common problems
  • Discuss key techniques to ensure success

A live question and answer session will follow the presentation. The webinar is ideal for metallurgists, metallographers and specimen preparation technicians, new engineers, quality control and laboratory personnel in any metallography facility new to the area or looking for a refresher on preparation and analysis of failed components.

Registration is complimentary and a replay will also be available. Attendees will receive a Certificate of Participation after the Webinar. To register for the complimentary webinar visit http://www.buehler.com. If the Webinar interests you, but the date does not suit you, simply register to receive the recording shortly after the event. Additional upcoming topics are also listed at the bottom of the Buehler webinar registration page.

Since 1936, the company has been a leading innovator in metallographic and hardness testing equipment and consumables for material specimen preparation. Contact a Buehler expert today! For additional information on Buehler’s products for material analysis or hardness testing, please visit http://www.buehler.com.

Buehler, an ITW Company maintains an extensive global network of laboratory, sales, distributors and service teams that are available to meet virtually or in person with customers worldwide. The Asian business office and plant is in Shanghai, China +86 400 111 8683 Email: Info.cn@buehler.com. Buehler also has an office in Japan +81 3 5439 5077 Email: info.japan@buehler.com. For additional information, email: marketing@buehler.com.

Share article on social media or email:

iThera Medical leads €1.9m research project to advance optoacoustic imaging technology towards AI-supported quantitative medical diagnosis


We are extremely excited to lift clinical diagnostics to a new level through the introduction of groundbreaking AI technology in an MSOT device. This will make the technology applicable to a wider patient population.

Multispectral optoacoustic tomography (MSOT) is an innovative, non-invasive diagnostic imaging method that provides information about tissue status based on the detection of disease biomarkers. The fundamental technology has already demonstrated its clinical value through numerous clinical pilot trials in a variety of disease areas – including in IBD, where MSOT may offer an effective alternative to the highly invasive gold standard procedure of colonoscopy to monitor disease status.

Commenced on 1st September 2021, the project DeepOPUS (highly integrated DEtEction Platform for improved quantification and increased framerate in OPtoacoustic and UltraSound imaging) aims to further advance the established MSOT technology through use of AI. These developments will enhance diagnostic and computational performance as well as reduce the cost of the device. Led by Munich-based iThera Medical in partnership with the Institute for Biological and Medical Imaging (IBMI) and the Institute for Computational Biology (ICB) of the Helmholtz Center Munich, DeepOPUS will encompass both hard- and software developments to the current MSOT technology.

A primary goal of the project is to increase the MSOT image quality with advanced AI methods for better usability and higher diagnostic accuracy. Furthermore, the advances made under DeepOPUS will enable fast ultrasound imaging to compete with state-of-the-art clinical sonography and thus facilitate adoption of MSOT in a routine clinical setting. Finally, a more compact and efficient design will result in an electronics platform that is both half the size and half the cost compared to the present version.

Stefan Morscher, project leader of DeepOPUS and VP of Software Development at iThera Medical, relays his enthusiasm: “We are extremely excited to lift clinical diagnostics to a new level through the introduction of groundbreaking AI technology in an MSOT device. This will make the technology applicable to a wider patient population.”

Dr. Dominik Jüstel, research group leader at IBMI and ICB, adds: “I am very keen to see algorithmic advances at our institute leveraged in such close collaboration with an industry partner to have a direct impact on MSOT imaging in the clinics.”

DeepOPUS marks a key step towards establishing MSOT as a competitor in the broader medical imaging market, where the technology promises to deliver meaningful benefits to clinicians and their patients.

About iThera Medical

Since its incorporation in 2010, iThera Medical develops and markets optoacoustic imaging systems for preclinical and clinical research. More recently, the company has started translating its technology for routine diagnostic clinical use across various types of diseases, including cancer, inflammatory, fibrotic, and cardiovascular diseases. Optoacoustic imaging utilizes the photoacoustic effect – the conversion of light energy into acoustic signals – to visualize and quantify optical contrast in deep tissue, at high spatial and temporal resolution. For details see: http://www.ithera-medical.com

The DeepOPUS project is funded through the Bavarian Ministry of Economic Affairs, Regional Development and Energy (Bayerisches Staatsministerium für Wirtschaft, Landesentwicklung und Energie) under grant agreement No DIE-2106-0004 // DIE0161/01. The material presented and views expressed are the responsibility of the author(s) only. The Bavarian state takes no responsibility for any use made of the information set out.

Share article on social media or email:

Shady Grove Fertility (SGF) Celebrates 30 Years and 100,000 Babies Born with ‘Moments Made Possible’ Campaign


SGF celebrates two milestones with its Moments Made Possible campaign: 30 years of SGF and 100,000 babies born.

“While the treatment of infertility has advanced tremendously over the past 30 years, one thing that hasn’t changed is SGF’s healthy obsession for never settling for the status quo. … We have consistently lived by the mantra to ‘always do what’s best for our patients.'”

Shady Grove Fertility (SGF), a national leader in fertility care, announced today it has reached a momentous milestone: 100,000 babies born from 30 years of continuous innovation, a commitment to research, and by offering hope.

SGF first opened its doors with two founding physicians, Michael J. Levy, M.D., and Art Sagoskin, M.D., in 1991 to the Rockville, Maryland community. Because of its ‘patient comes first’ approach to care, more than 70 physicians have joined the practice since with expansion across 41 offices now open (with a 42nd opening within the month in Brooklyn), seven states and Washington, D.C., an international location in Santiago, Chile, and international partner clinics throughout the UK and Canada.

“While the treatment of infertility has advanced tremendously over the past 30 years, one thing that hasn’t changed is SGF’s healthy obsession for never settling for the status quo,” says Dr. Levy, IVF Director, who sees patients in Rockville, MD, and internationally through SGF’s renowned Donor Egg Program. “With a practice our size coupled with our partnerships with four leading reproductive endocrinology and infertility (REI) training programs and a full-time clinical research team inhouse, individuals and couples benefit from advanced care that continuously evolves and improves. We have consistently lived by the mantra to ‘always do what’s best for our patients’ — this has served our patients and staff very well through the years.”

Today, SGF operates 11 state-of-the-art embryology labs in Atlanta, GA; Chesterbrook, PA; Denver, CO; Fairfax, VA; Manhattan, NY; Norfolk, VA; Richmond, VA; Rockville, MD; Tampa, FL; Towson, MD; and Santiago, Chile, offering the most sophisticated technology in the field to improve patient outcomes.

SGF believes that leadership is not a position or a title, it’s an action and an example, which is why they embrace their size and believe their prominence positions them in a seat of leadership. “We take that responsibility very seriously, which is why we invest heavily in training the next generation of physicians, serving the professional community as society leaders, publishing our scientific discoveries, and taking advantage of myriad educational platforms both domestically and internationally to advance the field,” shares Robert Stillman, M.D., SGF Medical Director Emeritus.    

SGF performed more than 17,000 assisted reproductive technology (ART) cycles in 2019 and is among the founding partners of US Fertility, the largest physician-owned, physician-led partnership of top-tier fertility practices in the U.S., which tops the list for most fresh non-donor in vitro fertilization (IVF) cycles, the most fresh donor cycles, the most frozen donor cycles, the most donor embryo cycles, and — of key importance — the most live births from fresh non-donor IVF cycles in women ages 35 and younger.

“In the early days of SGF, we set out to be the best by simply creating a culture that valued taking care of one patient at a time. By following that model, the demand continued to grow, which gave us the opportunity to increase accessibility to top-quality care in more regions,” says Mark Segal, former CEO of SGF for 25 years, and now CEO of US Fertility. “Now that SGF is part of the US Fertility partnership, we’ve developed an even greater culture that nurtures and energizes great talent, invests in recruiting, selecting, and growing the right people, and intensely focuses on innovation and collaboration to drive efficiency at all levels, all while refining a supportive infrastructure that’s built not only for enormous growth but also to enhance the patient experience.”

SGF’s fertility specialists provide basic and advanced treatment to overcome infertility, as well as fertility preservation and LGBTQ family building. SGF’s success rates continuously rank well above the national average and their high-risk, high-order multiple birth rate is less than one percent, among the lowest in the nation.

“The singular goal that all of our physicians have in common is to help more people build their families,” shares Dr. Sagoskin, who sees patients in Rockville, MD. “This is universal throughout our practice and the reason our teams work tirelessly to care for our patients. Earning their trust and being there to support them through the highs and lows on their pursuit to building their family is what it’s all about. At the end of the day, our team knows they give our patients their all.”

Over the course of SGF’s tenure, by focusing on improving patients’ overall experience, SGF has become well known for providing award-winning care, with many of the SGF physicians having earned top doctor distinctions and accolades. “While the awards and recognition are well appreciated and never taken for granted, the greatest joy and satisfaction comes from our patients. People are counting on us, and we never take that lightly,” adds Dr. Sagoskin.

“Aside from the 100,000 babies to our credit, one of our proudest accomplishments that keeps us humble and extra vigilant every day is having earned the trust of over 5,000 physicians who refer their patients to us annually for fertility care,” says Eric A. Widra, M.D., SGF Chief Medical Officer. “Our referring provider community has come to expect from us the highest of clinical standards and uncompromising patient service. They know that we will leave no stone unturned when it comes to helping patients achieve their dream of a family.”

A 2019 national study conducted of obstetricians/gynecologists (OB/GYN) revealed that the majority of respondents believe that when referring a patient to a fertility specialist, they look for good success rates and positive patient experiences first and foremost.

“We believe that any decision we make from the perspective of serving the patient will ultimately be the best choice,” says Ryan Martin, M.D., of SGF’s Warrington, PA office. “Therefore, we remain dedicated to delivering the most comprehensive, efficient, fiscally responsible, and compassionate care possible.”

Among contributions to SGF’s credit — now revered as a game-changer in how patients gain access to quality more affordable fertility care — was SGF’s Shared Risk 100% Refund Program for IVF and Donor Egg.

SGF was one of the first fertility practices in the country to create such a program in its early years and since has enrolled more than 25,000 patients. SGF’s unique 100% refund guarantee programs offer a financial safety net by providing qualified patients with the opportunity to pay a flat fee for up to six IVF or donor egg cycles and any subsequent frozen embryo transfers from those cycles. Patients either take home a baby or receive a full refund.* An estimated 82% of participants take home a baby.

“Among the factors that set SGF apart is we designed the first-of-its-kind guarantee program to be affordable and inclusive,” adds Dr. Levy. “The majority of patients meet the program criteria and close to 40 percent will become pregnant on their first try.”

SGF was also among the first practices to incorporate psychological support services into its treatment approach. “Treatment at SGF doesn’t just involve caring for patients’ medical needs, our integrated care model offers psychological support services by SGF’s licensed social workers,” adds Dr. Martin. “By helping to support the ‘whole’ patient, the aim is to reduce the stress and emotional toll that is often associated with infertility.”

Another reason SGF delivers optimal patient care is because of their individualized approach. “There is no one size fits all when it comes to determining the best course of treatment for patients,” adds Desireé McCarthy-Keith, M.D., M.P.H., of SGF’s Atlanta, GA location. “We base our treatment recommendations on a variety of circumstances including a patient’s test results, age, medical history, previous fertility treatment, and personal preferences. With all of these variables, we customize and optimize each treatment plan to meet the unique needs of each patient with the ultimate goal of offering patients the best chance of pregnancy.”

SGF’s ‘Moments Made Possible’ Campaign

SGF is commemorating these accomplishments that led es born over the course of 30 years with its ‘to 100,000 babies born over the course of 30 years with its ‘Moments Made Possible’ campaign. Whether patients are just beginning treatment or have a 30-year-old SGF “baby,” SGF is inviting the SGF community to add their voice and moments at #MomentsMadePossible on social media.

“The fertility journey is made up of moments—some big, like hearing a baby’s heartbeat, and some small, like the time a nurse said just the right thing on a day a patient needed encouragement the most,” shares Dr. Levy. “On our 30th anniversary, we honor and celebrate all the moments made possible if not for the sheer grit and resilience of our patients as well as the tireless efforts of the entire SGF care team. This campaign celebrates moments that happen while patients are in our care and those moments beyond, like baby’s first steps, a child winning that soccer championship, your son’s high school graduation, or father and daughter walking arm in arm down the aisle.”

“A patient’s relationship with SGF is lifelong,” adds Dr. Sagoskin. “Your moments matter to us long after you leave our care. We’re now celebrating many of our first SGF babies now grown having babies of their own. When you come to SGF you become part a 30-year strong community. You become part of our family.”

Speaking of community, SGF offers a comprehensive website and blog, as well as active Facebook, Instagram, and YouTube channels, where current and prospective patients will find a wealth of support and resources.

“While we joyfully celebrate 100,000 babies born, what we do is so much more than a tally of babies born,” says Vicki Gerber, SGF Executive Managing Director. “The magnitude of our efforts reverberates for many years and generations to come. Every team member at SGF is an integral part of the care community. We take pride that our mission is one of restoring hope when it’s lost, calming fears in the face of uncertainty, and offering solutions after a setback. And we do it with an assembly of professionals who have the biggest hearts. That’s what makes SGF truly special.”

(*Some exclusions may apply, please talk with an SGF Financial Counselor to learn more.)

About Shady Grove Fertility (SGF)

SGF is a leading fertility and IVF center of excellence with more than 100,000 babies born. With 41 locations, including new locations in Colorado and Norfolk, VA, as well as throughout CO, FL, GA, MD, NY, PA, VA, D.C., and Santiago, Chile, SGF offers patients virtual physician consults, delivers individualized care, accepts most insurance plans, and makes treatment more affordable through innovative financial options, including 100% refund guarantees. More physicians refer their patients to SGF than any other center. SGF is among the founding partner practices of US Fertility, the largest physician-owned, physician-led partnership of top-tier fertility practices in the U.S. Call 1-888-761-1967 or visit ShadyGroveFertility.com.

About US Fertility

US Fertility is the largest, physician-owned and physician-led, integrated network of top-tier IVF/fertility practices in the United States, offering comprehensive fertility-market-focused non-clinical, technology and management platforms that help domestic and international practices improve patient outcomes, while increasing patient access and demand. To learn more about partnership- or affiliate-status benefits, call 914-908-3289 or visit http://www.USFertility.com.

Sentien Biotechnologies Partners with BARDA to Evaluate High Dose Cohort in Phase 1/2 Trial of SBI-101 for Treatment of Acute Kidney Injury Associated with Sepsis


News Image

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to evaluate Sentien’s ex vivo cell therapy, SBI-101, in patients suffering from acute kidney injury (AKI) associated with sepsis. This patient population includes COVID-19 patients with sepsis-AKI.

The BARDA-Sentien collaboration will enable evaluation of high dose SBI-101 therapy for the first time and support regulatory path activities to advance its development for the treatment of sepsis.

SBI-101 is a combination product that integrates allogeneic mesenchymal stromal cells (MSCs) within an extracorporeal, blood-contacting device. MSCs are a unique source of therapeutic secreted factors that modulate the immune-mediated inflammatory response to acute organ injury. By keeping the MSCs confined within a blood-contacting device, SBI-101 enables controlled, dynamic, and sustained delivery of MSC-secreted factors to the patient’s blood, without the need for direct injection of the MSCs themselves. SBI-101 integrates into a standard blood circuit such as used with renal replacement therapy, thereby providing patients with both standard-of-care and MSC-mediated blood conditioning in a single session.

Sepsis occurs when an infection or other insult to the body produces a dysregulated host response in a patient, which can cause serious tissue damage, organ failure and even death. Patients presenting with severe, systemic inflammation have limited therapeutic options, and approaches that target pathogens may not be sufficient once a dysregulated response to an infection has started. In the current coronavirus pandemic, ICUs worldwide are caring for COVID-19 patients with sepsis and there are currently no host-targeted sepsis therapeutic products that are FDA-approved and available.

“We are grateful to BARDA for recognizing the potential impact of SBI-101 and awarding the funds to undertake this work,” said Sentien CEO, Brian Miller. “We have long believed that SBI-101 has broad therapeutic applicability; acute inflammatory disorders, like sepsis, can arise from almost any infection (including from COVID-19), so the impact of a new treatment option would be far-reaching.”

“There is a compelling scientific rationale for studying SBI-101’s effect on sepsis,” said Sentien Chief Medical Officer, Dr. Allen Nissenson. “The serious clinical consequences of sepsis are mediated by a dysregulated immune response; SBI-101 is designed to re-educate and normalize the patient’s immune response. We are encouraged by what we previously observed in the first cohort of this study and are eager to continue pursuing the therapeutic hypothesis that treatment with SBI-101 will restore a favorable immune response and result in improved clinical outcomes.”

The multi-center trial is a randomized, controlled, ascending dose Phase 1/2 study in patients with sepsis-AKI requiring RRT. The primary objective of the trial is to evaluate the safety and tolerability of SBI-101; endpoints for efficacy and pharmacodynamic responses to SBI-101 therapy will also be evaluated.

Please visit https://clinicaltrials.gov/ct2/show/NCT04445220 for more information about the study.

About Sentien Biotechnologies

Sentien Biotechnologies, Inc. is a privately held, clinical-stage company developing novel ex-vivo cell therapy applications to treat conditions caused by systemic, immune-mediated inflammation. Sentien’s lead product, SBI-101, integrates allogeneic mesenchymal stromal cells (MSCs) within an extracorporeal, hollow-fiber device. By immobilizing MSCs within a blood-contacting device, SBI-101 enables controlled, dynamic, and sustained delivery of MSC-secreted factors to the patient’s blood, without the need for direct injection of the MSCs themselves.

SBI-101 has been evaluated in a Phase 1b/2a study in subjects with dialysis-requiring acute kidney injury (AKI-D). An initial readout from the study provides preliminary evidence of anti-inflammatory and wound healing effects consistent with the SBI-101 therapeutic hypothesis.

Sentien’s technology can be applied to additional systemic inflammatory indications in both acute and chronic diseases, focusing on complex conditions where single-factor agents have not been effective.

For more information, please visit http://www.sentienbiotech.com.

Share article on social media or email:

TeselaGen Biotechnology Teams Up with iGEM to Advance Synthetic Biology in Developing Countries


iGEM 2019

TeselaGen is one of the most innovative start-ups in this space. By using TeselaGen’s Design & Build modules, our students gain valuable experience with the most advanced digital tools available to design better projects faster.

TeselaGen Biotechnology announced today that it has partnered with the iGEM Foundation to support the iGEM Design League, a new competition that aims to advance synthetic biology, starting with Latin America. As part of the collaboration, students will have access to the TeselaGen® operating system for biotechnology to design projects that solve critical local problems using synthetic biology.

“The iGEM Design League, our newest program, is focused on the design step of the synthetic biology cycle as a framework for biology, and we are thrilled to be partnering with TeselaGen,” said Meagan Lizarazo Executive Vice President, iGEM Foundation. “TeselaGen is one of the most innovative start-ups in this space. By using TeselaGen’s Design & Build modules for building biological molecules, our students gain valuable experience with the most advanced digital tools available to design better projects faster.”

The iGEM Design League begins this year as a pilot program in Latin America to accelerate synthetic biology in the region and to contribute to the development of future biological engineers. The competition will consist of approximately 300-400 students primarily from universities spanning 8 countries in Latin America. The 25 teams will compete over the course of the year, with the finalist’s presentation live-streamed during the iGEM 2021 Giant Jamboree in November.

Along with providing access to its platform, TeselaGen will also be participating in educational portions of the iGEM Design League by hosting lectures and workshops on synthetic biology. “As part of the synthetic biology community and long-term supporters of iGEM, we are very pleased to collaborate on this new project,” said TeselaGen CEO Eduardo Abeliuk, Ph.D. “Latin America’s high-quality STEM college programs are contributing to a growing workforce of smart, enthusiastic scientists and engineers. This program is significant in that the students will have the opportunity to solve local problems in a real-world context by integrating design thinking and advanced computational tools, further enhancing their experience and hopefully contributing to the development of local innovations. This is how you develop talent and advance the bioeconomy.”

The International Genetically Engineered Machine Foundation, better known as iGEM, began more than 17 years ago as an independent non-profit organization dedicated to advancing synthetic biology, education, and competition by developing an open and collaborative community. Approximately 3000 teams have participated in the iGEM competition, generating hundreds of prototypes of solutions to local and global problems in health, the environment, manufacturing, and more.

About TeselaGen Biotechnology

TeselaGen has developed the first artificial intelligence-enabled operating system for biotechnology, enabling scientific organizations to commercialize high-performance bioproducts – from pharmaceuticals to food to fabrics – faster and easier than ever. The TeselaGen® operating system connects biologists, lab technicians, and bioinformaticians so that they can collaboratively design and build experiments, organize and standardize data and then test and continually learn. TeselaGen has been deployed by Fortune 50 companies and emerging innovators in biopharmaceuticals, agriculture, and specialty chemicals. The company is privately held and based in San Francisco, CA. For more information, visit http://www.teselagen.com

About iGEM

iGEM (International Genetically Engineered Machine) Foundation is an independent, non-profit organization that pioneered the synthetic biology industry and continues to advance the field through education, competition, and industry collaboration. iGEM’s annual student competition is the largest synthetic biology innovation program and a launchpad for the industry’s most successful leaders and companies. The After iGEM program supports the competition’s 50,000+ participants in their future endeavors to continue to work toward a strong, responsible, and visionary synthetic biology industry. For more information, visit http://www.igem.org

Share article on social media or email:

INDIGO Biosciences Expands Portfolio for Preclinical Development and Oncology Research


INDIGO Biosciences Logo

FGFR plays a key role in the development and function of most of the body’s vital organs, and understanding how even small mutations can lead to disease onset and progression is crucial for development of potential screening and treatment methods.

INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust preclinical testing portfolio to include a new Fibroblast Growth Factor Receptor 1&2 (FGFR1/2) assay primarily implicated in diabetes, kidney disease, and the progression of certain cancers. This cell-based in vitro assay provides discovery researchers with the ability to quickly make critical decisions about potential drug candidates before moving into trials.

“FGFR 1/2 represents an important addition to our preclinical portfolio, especially for oncology researchers,” says Dr. Jack Vanden Heuvel, Chief Scientific Officer of INDIGO. “Because the receptor plays a key role in the development and function of most of the body’s vital organs, understanding how even small mutations can lead to disease onset and progression is crucial for development of potential screening and treatment methods.”

FGFR 1&2 regulate a variety of cellular functions including migration, proliferation, differentiation, metabolism, and survival. In particular, FGFR signaling plays a critical role in regulating metabolism in the kidney, liver, brain, intestine, and adipose tissues. Perhaps not surprisingly, dysfunctional FGFR signaling can lead to a range of physiological disorders. For example, mutations may result in abnormal morphogenesis and the progression of several types of cancer, including non-small cell lung cancer, breast cancer, liver cancer, and colorectal cancer, among others. Consequently, the FGF receptors continue to command much interest as targets for drug development and drug safety screening.

In vitro assays, such as those offered by INDIGO, provide important early indications of a compound or antibody’s potential for progressing to further development and clinical testing. INDIGO’s assays allow researchers to definitively determine what receptors are affected to ensure the selectivity of target compounds, a key piece of information necessary to proceed with development. The new FGFR1/2 reporter assay is available both as a screening service or as an all-inclusive kit.

About INDIGO Biosciences, Inc.

INDIGO Biosciences, Inc. is a leading provider of nuclear receptor and in vitro toxicology solutions that accelerate scientific decision-making. INDIGO supplements the world’s largest portfolio of nuclear receptor kits and services and in vitro toxicology solutions with greater results readability, reproducibility, and faster turnaround times. Our solutions, plus supportive team and reliable science and platforms aim to reduce the time, cost, and risk associated with the discovery process. Learn more at http://www.indigobiosciences.com.

Share article on social media or email: